secwatch.observer — SEC 8-K summary
======================================

Issuer:     Guardant Health, Inc. (GH)
CIK:        0001576280
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001193125-25-005319
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Guardant Health reports preliminary Q4 revenue ~$200M (+29% YoY); FY24 revenue $737M (+31%)
--------------------------------------------------------------------------------

- Total revenue Q4 ~$200M (+29% YoY); full year ~$737M (+31% YoY).
- Oncology clinical tests (ex-Shield) Q4 57,300 (+24%); full year 206,700 (+20%).
- Biopharma tests Q4 11,050 (+16%); full year 40,500 (+35%).
- Shield screening tests Q4 6,400 with ~$4M revenue in first full commercial quarter.
- Free cash flow -$84M in Q4, -$275M full year; cash & securities $944M at Dec 31, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576280/000119312525005319/0001193125-25-005319-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576280/000119312525005319/d890861d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-005319

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer